Tetracycline Versus Doxycycline for HP Rescue Therapy
Launched by SHANGHAI ZHONGSHAN HOSPITAL · Aug 22, 2021
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participate in the trial voluntarily, fully understand the trial, and sign the informed consent form (ICF).
- • 18-75 years old on the day of signing the ICF.
- • Helicobacter pylori infection confirmed by 13C-urea breath test or rapid urease test.
- • Have failed eradication treatment before.
- Exclusion Criteria:
- • Have not received Hp eradication treatment.
- • Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine, and psychiatric diseases.
- • Subjects or guardians refused to participate in the trial.
- • Alcohol and/or drugs Abuse (addiction or dependence) or poor compliance with doctor's judgment.
- • Have taken antibiotics, bismuth, PPI or Chinese traditional medicine 4 weeks before treatment.
- • Pregnant or lactating women.
- • Active peptic ulcer.
- • allergic to drugs used in the trial.
- • any other circumstances that are not suitable for recruitment.
Trial Officials
Taotao Liu, MD
Principal Investigator
Fudan University
About Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital is a prestigious medical institution affiliated with Fudan University, renowned for its commitment to advancing healthcare through rigorous clinical research and innovative patient care. With a focus on multidisciplinary collaboration and cutting-edge medical technologies, the hospital conducts a wide range of clinical trials aimed at improving treatment outcomes across various specialties. Its state-of-the-art facilities and highly qualified research team ensure that trials adhere to the highest ethical and scientific standards, contributing significantly to the global body of medical knowledge and enhancing patient health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials